SLC6A3 and Parkinson disease: Recently, long-term follow-up of the PARS (Parkinson Associated Risk Syndrome) cohort confirmed baseline DAT as a strong predictor of conversion to clinical PD for persons with hyposmia and a DAT deficit [192].